Peptide appearance
Lyophilized form helps protect peptide quality. Peptides are supplied as a dry powder, which may look like a compact "puck" or a lighter powder inside the vial.
Because the peptide is dry, it does not require refrigerated shipping during normal transit, including warm seasonal conditions. For longer storage, follow the storage guidance in the product description.
Appearance can vary. The stated peptide content is checked through third-party analysis.
Read more in the product description.
Solution not bundled
Peptides are delivered as lyophilized powder. This dry form helps preserve peptide quality during storage and transport and does not require refrigerated shipping during normal transit.
To prepare a solution, use a solvent such as Bacteriostatic water. It is sold separately, so add it only when you need it for peptide preparation.
Read more in the product description.
Sleep Enhancement
DSIP
In stock
Order within — to ship today
Arrives 26 – 30 November to Europe
DSIP
55,50 €
Delta sleep-inducing peptide for neuropeptide, circadian, and stress-pathway studies.
Compound information
Specifications
Molecular profile
- Sequence
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
- Molecular mass
- 848.82 g/mol
- CAS number
- 62568-57-4
- Molecular formula
- C35H48N10O15
Material record
- Physical appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- Delta sleep-inducing peptide; supplied strictly for research use only.
Research overview
DSIP
DSIP Description
This interesting neuropeptide gets its name from animal research, when it was found to be able to induce deep sleep in rabbits. However, science is particularly interested in it because of its many physiological, endocrine and modulatory effects, such as its ability to alter corticotropin levels, inhibit somatostatin secretion, normalize blood pressure, reduce stress, influence sleep rhythms, or chronic pain perception. It even appears that it could find future application in the research of depression or cancer. Studies have found that DSIP can be classified as peptide neuromodulator. By activating special receptors in hypothalamus and brainstem it can influence the regulation of the sleep cycle resulting in enhancing deep sleep and minimizing insomnia and anxiety.
Overview of Published Research
The sleep inducing effects of DSIP were studied in numerous researches, which sometime were coming with different conclusions. The experts think that this problem may have arisen due to current testing methodologies where EEG measures of sedation are not based on natural but on pharmacological sedation. However, intravenous administration of synthetic DSIP in 6 middle-aged human chronic insomniacs with disturbed sleep brought very good results, as longer sleep, higher quality with fewer interruptions and slightly more REM sleep. Therefore, this study showed that DSIP can normalize human sleep regulation.
These perhaps most significant findings regarding DSIP have been confirmed in other studies, which have shown that DSIP improves sleep structure and efficiency, and reduces sleep latency in chronic insomnia compared to placebo. Thus, overall, polysomnographic studies indicate greater sleep efficiency with DSIP administration, it has probably not major observed effect on short-term treatment of chronic insomnia.
It is obvious, that the neuropeptide is definitely somehow related to sleep onset. Numerous subjective indicators from research on DSIP effects in humans suggest that the peptide does indeed promote sleep, inducing feelings of drowsiness, increasing sleep by 59% within a 130-min interval after the treatment, as compared to placebo, and shortening sleep onset as well. However, these subjective findings are contradicted by EEG analyses, which in contrast revealed no apparent sedation in the classic pharmacologic way. DSIP in humans can thus sustain natural sleep functions, and is well tolerated, with no obvious side effects observed.
Alternative options for the treatment of chronic pain are indeed of a very urgent medicine interest. A preclinical pilot study in human patients with chronic pain episodes found, that DSIP significantly reduced pain perception, also improved mood by reduction of depressive states, and that it may potentially be of interest for research into physiological addiction on pain medications, as it was observed to reduce withdrawal symptoms that occurs after discontinuation of long-term analgesic treatment. Experimental results showed a modulation interaction of DSIP with endogenous opioid-peptidergic systems and exogenous intracerebrally or systemically administered morphine and amphetamine. This encouraged the research for a possible action of the peptide in humans suffering from chronic pronounced pain episodes. 7 patients with migraine episodes and vasomotor headaches, chronic tinnitus and psychogenic pain attacks were studied, and after intravenous administration on 5 consecutive days followed by 5 injections every 48-72 h, DSIP lowered the pain levels of 6 out of 7 patients significantly.
Although both DSIPs and opioid drugs act on the same receptors in the CNS, as has been found in research in rat models, there is as yet no indication at all that the administration of DSIPs causes a similar addiction. These results show that DSIP produces an antinociceptive effect by acting at the supraspinal level. This effect is mediated via the opioid receptor, either directly or indirectly. DSIP may thus play an important role in pain regulation in the central nervous system.
DSIP has been shown to restrict stress-induced changes in mitochondrial monoamine oxidase type A (MAO-A) and serotonin levels. Metabolic effects of DSIP under hypoxia stress were investigated in rats subjected to short-term hypoxic conditions. These findings led to the investigation of the mechanism by which DSIP may alter mitochondrial activity in a hypoxic environment, suggesting that the peptide could also have an effect on the course of depression. Given the strong link between sleep function and depressive states, this peptide, which appears to influence the sleep cycle, could also be of research interest in the context of depression onset.
Patients suffering from major depression had reduced levels of immunoreactive DSIP compared to control subjects, as shown in cerebrospinal fluid (CSF) analysis. However, no one has yet conducted trials where they have attempted to treat depression by normalizing DSIP levels. Reduced CSF concentrations have been described in patients with schizophrenia. The peptide is associated with changes in the hypothalamic-pituitary-adrenal axis, and this may play role in suicidal patients with major depressive disorder with altered DSIP-like immunoreactivity levels. It seems, that DSIP passes the blood-brain barrier more easily than many other neuropeptides.
Neuromodulatory DSIP could help to compensate pathological metabolic damage in various animal species and humans, that is caused by oxygen deprivation in the body, preserving normal mitochondrial function and protecting tissue until proper blood flow is restored. That DSIP reverses stress-induced metabolic disturbances, was suggested by research conducted in rats. Thus, it can be hypothesized that the ability of DSIP to maintain efficiency of oxidative phosphorylation, even in the setting of hypoxia, could make the peptide a subject of interest for conditions such as stroke and heart attack in future research.
DSIP could be a very potent antioxidant because it reduces free radical production by preserving normal mitochondrial function. The revealed capacity of DSIP to increase the efficiency of oxidative phosphorylation found in vitro experiments could contribute to understanding pronounced stress protective and antioxidant action of this peptide in vivo.
Research has indicated a potential area of interest for DSIP in the study of withdrawal symptoms from opiate and alcohol addictions, which has been supported by the results of studies in animals conducted by Tissot and the fact, that DSIP possesses an agonistic activity on opiate receptors. Complete disappearance or significant improvement of withdrawal symptoms was confirmed by 97% of alcohol-addicted patients and 87% of opiate-addicted patients in clinical study of 107 patients treated via DSIP. Anxiety, however, was slower to decrease, and opioid withdrawal required more DSIP injections over a longer period of time. Good was also the tolerance, except of few headaches reported.
As a clinical study done in mice suggests, DSIP may demonstrate notable effects in the context of cancer research, with outcomes more pronounced than those of some vaccines or medicines tested to date. Treated female mice that were given DSIP from three months of age until they died, for 5 consecutive days each month, showed a 2.6-fold decrease in tumor development and a 22.6% lower frequency of chromosomal defects in the bone marrow cells; it did not influence mean life span; and it increased by 17.1% life span of the last 10% of the survivors and by 24.1% maximum life span in comparison with the control group.
DSIP is also being tested as an adjuvant in cancer research. A recent study suggests that DSIP may correct or even prevent CNS changes that are side effects with chemotherapy. Children undergoing chemotherapy treatment are particularly vulnerable in this regard. These may include, for example, impaired motor control, behavioral changes such as depression and language problems. The selective effects of DSIP on the blood supply to the brain explain at least part of this effect. Indeed, DSIP and its alternative preparation Deltaran significantly increase blood supply during CNS stress such as chemotherapy or even ischemia. Rats with cerebral ischemia given Deltaran survived 100% of the time compared to 62% in the control sample. The study in mice also found that treatment with Deltaran significantly decreased total spontaneous tumor incidence (by 2.6-fold), mainly mammary carcinomas and leukemias as compared with the control group. This was by the way the first report on geroprotector and anticarcinogenic effect of DSIP-containing preparation Deltaran.
Where and how DSIP is synthesized is not yet known. The peptide's primary function may not ultimately be sleep at all, although it is most closely associated with sleep cycle regulation, because DSIP levels are the same in CNS tissues as in peripheral tissues, suggesting that the peptide may also be formed outside the CNS. It has several physiological effects, such as modification of heart rate, blood pressure, pain threshold and some lymphokine system functions.
Just as growth hormone regulates not only bone and muscle growth but has much broader functions, DSIP may be a hypothalamic hormone regulating more than just the sleep cycle. Thus, it seems that DSIP may indeed play a role in altering physiology in preparation of the body for sleep, as some of it effects occur before neurological and behavioral signs of sleep.
DSIP contributes to hypertrophy and hyperplasia in skeletal muscle by inhibiting somatostatin, a protein that is produced in muscle cells and acts on muscle growth. The inhibition of somatostatin by DSIP has been found by a separate study, thus leading to the speculation that this peptide might have larger and more universal functions regarding human physiology than just primary sleep promotion, for which the direct inhibitory effects of somatostatin are more than peculiar.
For laboratory purposes and personal observation only. Not for human consumption.
Laboratory care
Handling
Peptides in transport
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Storage of lyophilized peptides
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Up to 3 months
- Refrigerated (2–8 °C): Up to 6 months
- Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Storage of reconstituted peptides
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
- Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Analytical documentation
Tests
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 10mg

99.7%Purity by HPLC
Recorded QC panel
- AssayPeptide Screening 0.1% TFA
- 14.13 mg (± 0.07 mg)
- PurityPeptide Screening 0.1% TFA
- 99.7%
- Identity (FTIR)Peptide Screening 0.1% TFA
- 983 (± 5)
- Identity (RT)Retention time
- 0.992 (± 0.005)
- Bacterial endotoxinUSP 85 / Eur. Ph. 2.6.14
- 0.335 EU/mg
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Source record
References
"The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep | SpringerLink." [Online]. Available: https://link.springer.com/article/10.1007%2FBF01971753. [Accessed: 25-Jun-2019].
"Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/3622582. [Accessed: 25-Jun-2019].
"Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/1299794. [Accessed: 25-Jun-2019].
"Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/6895513. [Accessed: 25-Jun-2019].
"Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/6548970. [Accessed: 25-Jun-2019].
"Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP). - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/2853064. [Accessed: 25-Jun-2019].
"Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypo... - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/12668217. [Accessed: 25-Jun-2019].
"Effects of delta-sleep inducing peptide (DSIP) and some analogues on the activity of monoamine oxidase type A in rat brain under hypoxia stress. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/7628639. [Accessed: 25-Jun-2019].
"Decreased concentrations of delta-sleep inducing peptide in plasma and cerebrospinal fluid from depressed patients: Nordisk Psykiatrisk Tidsskrift: Vol 39, No sup11." [Online]. Available: https://www.tandfonline.com/doi/abs/10.3109/08039488509101959. [Accessed: 25-Jun-2019].
"Delta sleep-inducing peptide (DSIP): An overview of central actions and possible relationship to psychiatric illnesses: Nordisk Psykiatrisk Tidsskrift: Vol 42, No 2." [Online]. Available: https://www.tandfonline.com/doi/abs/10.3109/08039488809103215. [Accessed: 25-Jun-2019].
"High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/9606527. [Accessed: 25-Jun-2019].
"Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/9617990. [Accessed: 25-Jun-2019].
"DSIP in the treatment of withdrawal syndromes from alcohol and opiates. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/6548969. [Accessed: 25-Jun-2019].
"Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female ... - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/12782416. [Accessed: 25-Jun-2019].
A. B. Sinyukhin, G. P. Timoshinov, V. A. Kornilov, and P. D. Shabanov, "P.7.a.006 Delta sleep-inducing peptide analogue corrects the CNS functional state of children treated with antiblastomic therapy," Eur. Neuropsychopharmacol., vol. 19, pp. S681–S682, Sep. 2009.
E. V. Koplik et al., "Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection," Neurosci. Behav. Physiol., vol. 38, no. 9, pp. 953–957, Nov. 2008.
"DSIP--a tool for investigating the sleep onset mechanism: a review. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/3286557. [Accessed: 25-Jun-2019].
"[DSIP: the sleep peptide or an unknown hypothalamic hormone?]. - PubMed - NCBI." [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/7817664. [Accessed: 25-Jun-2019].
National Center for Biotechnology Information
PubChem Compound Summary: Delta sleep-inducing peptide
Authoritative identity record for DSIP.
PubChem View source ↗Chemical Abstracts Service
CAS Common Chemistry: 62568-57-4
Authoritative CAS Registry Number record for DSIP.
CAS Common Chemistry View source ↗Schoenenberger GA, Monnier M · 1977
Characterization of a delta-electroencephalogram (delta-sleep)-inducing peptide
Primary characterisation report for DSIP.
Proceedings of the National Academy of Sciences of the United States of America · 10.1073/pnas.74.3.1282 View source ↗Sukhanova TV, Artyukhov AA, Gurevich YM · 2014
Delta-sleep inducing peptide entrapment in the charged macroporous matrices
Primary materials study using DSIP.
Materials Science and Engineering C · 10.1016/j.msec.2014.05.059 View source ↗National Center for Biotechnology Information
PubChem compound record
PubChem View source ↗Schaison G, Jacquillat Cl, Weil M, Auclerc MJ, Curely JP, Bernard J · 1977
[Recurrence with gonadic localization of acute leukemia. 113 cases]
La Nouvelle presse medicale View source ↗Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA · 1981
Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior
International journal of clinical pharmacology, therapy, and toxicology View source ↗Bes F, Hofman W, Schuur J, Van Boxtel C · 1992
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
Neuropsychobiology View source ↗Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R · 1984
DSIP in the treatment of withdrawal syndromes from alcohol and opiates
European neurology View source ↗Larbig W, Gerber WD, Kluck M, Schoenenberger GA · 1984
Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study
European neurology View source ↗Schneider-Helmert D, Schoenenberger GA · 1983
Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep
Neuropsychobiology View source ↗Yehuda S, Carasso RL · 1988
DSIP--a tool for investigating the sleep onset mechanism: a review
The International journal of neuroscience View source ↗Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, Slashcheva GA, Prudchenko IA, Mikhaleva II, Khokhlova ON, Murashev AN, Ivanov VT · 2021
Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke
Molecules (Basel, Switzerland) View source ↗· 2019
The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep
· 10.1007/bf01971753 View source ↗· 2019
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia
View source ↗· 2019
Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP)
View source ↗· 2019
Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypo
View source ↗· 2019
Effects of delta-sleep inducing peptide (DSIP) and some analogues on the activity of monoamine oxidase type A in rat brain under hypoxia stress
View source ↗· 2019
Decreased concentrations of delta-sleep inducing peptide in plasma and cerebrospinal fluid from depressed patients: Nordisk Psykiatrisk Tidsskrift: Vol 39, No sup11
· 10.3109/08039488509101959 View source ↗· 2019
Delta sleep-inducing peptide (DSIP): An overview of central actions and possible relationship to psychiatric illnesses: Nordisk Psykiatrisk Tidsskrift: Vol 42, No 2
· 10.3109/08039488809103215 View source ↗· 2019
High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder
View source ↗· 2019
Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial
View source ↗· 2019
Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female
View source ↗A. B. Sinyukhin, G. P. Timoshinov, V. A. Kornilov, and P. D. Shabanov · 2009
P.7.a.006 Delta sleep-inducing peptide analogue corrects the CNS functional state of children treated with antiblastomic therapy
Eur. NeuropsychopharmacolE. V. Koplik et al. · 2008
Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection
Neurosci. Behav. Physiol· 2019
[DSIP: the sleep peptide or an unknown hypothalamic hormone?]
View source ↗Customer reviews
Quality products,fast shipping,great refferal plan,only downside is that products in 4 mounths since my first order got more and more expensive ,but overall verry good experience.
Read full review →More than 2 weeks for package dispatch. They promised one free peptide next time. Sent me new tracking number but package still wasn't delivered to fedex. Last package (much much cheaper) was delivered in less than week. I will update if they will send my package. ok,package sent.
Read full review →Extremely satisfied with the product quality and overall experience. The customer service is polite and quick. All recommendations!
Read full review →Great service!
Read full review →Always on time and customer care is super great
Read full review →Fast good, and quality is perfect
Read full review →ordered 3 times now and everything ok every time.
Read full review →Trustworthy site with a huge catalog of products. Been purchasing from them for some time now never got disappointed. I could only recommend them.
Read full review →Great quality product
Read full review →Everything was great, super customer support, honest, reliable
Read full review →Everything ok. With little problem with package, but after contact with Customer Service everything went right. Good quality of products
Read full review →Excellent. Buying peptides online can be nerve wracking! But Adria are very transparent about all the checks and certifications. My experience with them was excellent. Great products at good prices and efficient P&P
Read full review →



